India's bioeconomy has expanded nearly 20-fold in a decade. Critically analyse the drivers and the equity concerns.

India's bioeconomy — economic activity from biological resources and biotechnology — has grown from about $10 billion in 2014 to roughly $190 billion in 2026, with a target of $300 billion by 2030 [1][4]. The expansion is real and policy-driven, but its benefits remain unevenly distributed across regions, firms and social groups.

Drivers of the expansion

• Policy architecture: the BioE3 Policy, approved by the Cabinet on 24 August 2024, anchors high-performance biomanufacturing through Bio-AI Hubs, Biofoundries and Biomanufacturing Hubs [2].
• Startup ecosystem: biotech startups rose from about 50 in 2014 to several thousand today, incubated largely through BIRAC under the Department of Biotechnology [1][4].
• Crisis-tested capability: indigenous Covid-19 vaccine development demonstrated end-to-end capacity from R&D to mass manufacturing [1].
• Convergence and demand pull: AI-enabled biology, precision biotherapeutics, smart proteins and climate-resilient agriculture opened high-value segments [2].
• Institutional analogue: the parallel space reform — a single-window IN-SPACe and nearly 400 startups against one in 2014 — shows how regulatory liberalisation multiplies private entry [3].

Equity concerns

• Spatial concentration: activity clusters in a few biotech corridors and metros; the DBT–State partnerships under BioE3 are a corrective still at an early stage [2].
• Sectoral skew: growth is dominated by biopharma and bio-industrial segments, while bio-agriculture — where most livelihoods lie — contributes a smaller share [4].
• Access versus profit: precision biotherapeutics risk high pricing, straining affordable access consistent with Article 21's right to health.
• Benefit-sharing: commercial use of biological resources and traditional knowledge raises questions of fair returns to local communities under the biodiversity framework.
• Skill divide: value capture favours a small research-intensive workforce, limiting the "Employment" pillar's reach.

The 20-fold rise reflects genuine capability-building rather than statistical accident, yet scale alone is not development. Realising the $300 billion goal equitably requires decentralised biofoundries in lagging states, stronger bio-agriculture linkages for farmers, and transparent benefit-sharing — aligning BioE3's employment and environment pillars with SDG-10's promise of reduced inequality.